US Manufacturing Expansion

Novartis plans to Expand its US-based Manufacturing and R&D Footprint

The company will make a total investment of $23B over the next five years, creating:

Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
New manufacturing capacity: Novartis will be able to produce 100% of its key medicines end-to-end in the US, a significant increase from current levels
Increased R&D presence, including a new research hub in the San Diego area to tap some of the best and brightest minds in America.

Our planned $23 billion investment over 5 years in US-based infrastructure will ensure all key Novartis medicines for US patients will be made in the United States. This commitment enables Novartis to expand on its current manufacturing, research and technology presence across the country, creating nearly 1,000 new jobs at Novartis and approximately 4,000 additional US jobs. The production capacity will cover both active pharmaceutical ingredients (API) and biologics drug substance, as well as secondary production and packaging.

Read the Release

Interested in being considered for Novartis’s new US manufacturing sites? Please complete the form below.

First Name

Last Name

E-Mail

Organization

State

City (if applicable)

Are you authorized to speak on behalf of local or state Economic Development Office?

Yes

No

Are you an elected official or representing an elected official?

Yes

No

Please leave a brief description of your interest for the Novartis Site Planning Team

What office held?

Other email addresses to include if follow up is needed

We are collecting this information to review inquiries related to our build of future Novartis manufacturing sites in the US, in accordance with our Novartis Privacy Policy (www.novartis.us/privacy). Submissions will be reviewed by the Novartis Site Planning team, and a member of the team will get back to you.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.